PE20021098A1 - CD44v6 SPECIFIC ANTIBODIES - Google Patents
CD44v6 SPECIFIC ANTIBODIESInfo
- Publication number
- PE20021098A1 PE20021098A1 PE2002000422A PE2002000422A PE20021098A1 PE 20021098 A1 PE20021098 A1 PE 20021098A1 PE 2002000422 A PE2002000422 A PE 2002000422A PE 2002000422 A PE2002000422 A PE 2002000422A PE 20021098 A1 PE20021098 A1 PE 20021098A1
- Authority
- PE
- Peru
- Prior art keywords
- refers
- antibody
- specific antibodies
- proteins
- sequence
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
SE REFIERE A ANTICUERPOS CON UNA SECUENCIA ESPECIFICA, QUE SON ESPECIFICOS DE UN EPITOPO QUE ESTAN CODIFICADOS POR EL EXON v6 VARIANTE DEL GEN CD44 Y A DERIVADOS DE DICHO ANTICUERPO. SE REFIERE TAMBIEN A MOLECULAS DE ACIDO NUCLEICO QUE CODIFICAN DICHAS PROTEINAS ANTICUERPO. LA MOLECULA DE ANTICUERPO COMPRENDE UNA REGION VARIABLE DE LA CADENA PESADA CARACTERIZADA POR LA SECUENCIA DE AMINOACIDOS DEFINIDA EN LA SEQ ID No. 1 O UNO DE SUS FRAGMENTOS, VARIANTES ALELICAS, VARIANTES FUNCIONALES, GLICOSILACION, DERIVADOS QUIMICOS. SE REFIERE TAMBIEN A COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DICHAS PROTEINAS SIENDO UTILES PARA EL TRATAMIENTO DEL CANCERIT REFERS TO ANTIBODIES WITH A SPECIFIC SEQUENCE, WHICH ARE SPECIFIC TO AN EPITOPE THAT ARE CODED BY THE EXON v6 VARIANT OF THE CD44 GENE AND TO DERIVATIVES OF SUCH ANTIBODY. IT ALSO REFERS TO NUCLEIC ACID MOLECULES THAT CODE SUCH ANTIBODY PROTEINS. THE ANTIBODY MOLECULA INCLUDES A VARIABLE REGION OF THE HEAVY CHAIN CHARACTERIZED BY THE SEQUENCE OF AMINO ACIDS DEFINED IN SEQ ID No. 1 OR ONE OF ITS FRAGMENTS, ALLELIC VARIANTS, FUNCTIONAL VARIANTS, GLYCOSILATION, CHEMICAL DERIVATIVES. IT ALSO REFERS TO PHARMACEUTICAL COMPOSITIONS THAT INCLUDE SUCH PROTEINS BEING USEFUL FOR THE TREATMENT OF CANCER
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01112237 | 2001-05-18 | ||
| US32514701P | 2001-09-26 | 2001-09-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20021098A1 true PE20021098A1 (en) | 2003-02-11 |
Family
ID=33442672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000422A PE20021098A1 (en) | 2001-05-18 | 2002-05-17 | CD44v6 SPECIFIC ANTIBODIES |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1397387A1 (en) |
| JP (1) | JP2005504517A (en) |
| CN (1) | CN1541226A (en) |
| AR (1) | AR036154A1 (en) |
| BR (1) | BR0210905A (en) |
| CA (1) | CA2443437A1 (en) |
| CZ (1) | CZ20033476A3 (en) |
| EA (1) | EA200301169A1 (en) |
| EC (1) | ECSP034838A (en) |
| EE (1) | EE200300569A (en) |
| HU (1) | HUP0400030A3 (en) |
| MX (1) | MXPA03010523A (en) |
| PE (1) | PE20021098A1 (en) |
| PL (1) | PL365735A1 (en) |
| SK (1) | SK15592003A3 (en) |
| WO (1) | WO2002094879A1 (en) |
| YU (1) | YU91403A (en) |
| ZA (1) | ZA200307365B (en) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7189397B2 (en) | 1999-10-08 | 2007-03-13 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7947496B2 (en) | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US8071072B2 (en) | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US8048416B2 (en) | 1999-10-08 | 2011-11-01 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US20050100542A1 (en) | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| EP2316857A1 (en) * | 2004-02-12 | 2011-05-04 | Morphotek, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| WO2006099141A2 (en) | 2005-03-10 | 2006-09-21 | Morphotek, Inc. | Anti-mesothelin antibodies |
| JP2009521206A (en) | 2005-04-22 | 2009-06-04 | モルフォテック、インク． | Antibodies internalized into folate receptor alpha positive cells with immune effector activity |
| WO2008157369A2 (en) * | 2007-06-13 | 2008-12-24 | Zymogenetics, Inc. | Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus |
| EP2009028A1 (en) * | 2007-06-27 | 2008-12-31 | Monoclonal Antibodies Therapeutics | Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors |
| CA2786337A1 (en) | 2010-02-04 | 2011-08-11 | F. Hoffmann-La Roche Ag | A monoclonal antibody to cd44 for use in the treatment of head and neck squamous cell carcinoma |
| CN102337298B (en) * | 2011-08-19 | 2013-11-06 | 黄开红 | Immune nano-carrier for conveying siRNA (small interfering Ribonucleic Acid) and preparation method and application thereof |
| EP2788024A1 (en) | 2011-12-06 | 2014-10-15 | F.Hoffmann-La Roche Ag | Antibody formulation |
| WO2017215637A1 (en) * | 2016-06-15 | 2017-12-21 | 李翀 | Human endometrial cancer marker, antibody, and application of antibody |
| CN107556388A (en) * | 2016-06-30 | 2018-01-09 | 中国科学院深圳先进技术研究院 | The double targeting antibodies of anti-CD44v6 and CD3 specificity, the minicircle dna containing this pair of targeting antibodies expression cassette and application |
| JP2024512324A (en) * | 2021-03-05 | 2024-03-19 | ジーオー セラピューティクス，インコーポレイテッド | Anti-glycoCD44 antibodies and their uses |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0438310A1 (en) * | 1990-01-19 | 1991-07-24 | Merck & Co. Inc. | Method for producing recombinant immunoglobuline |
| GB9020282D0 (en) * | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
| CA2149635A1 (en) * | 1992-11-20 | 1994-06-09 | David Tarin | Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors |
| UA58482C2 (en) * | 1994-06-08 | 2003-08-15 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | MONOCLONAL ANTIBODY VFF-18 AGAINST CD44v6 AND ITS FRAGMENTS |
| UY24389A1 (en) * | 1995-12-06 | 2001-10-25 | Karlsruhe Forschzent | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF FLAT EPITHELIUM CARCINOMA |
-
2002
- 2002-05-17 EE EEP200300569A patent/EE200300569A/en unknown
- 2002-05-17 WO PCT/EP2002/005467 patent/WO2002094879A1/en not_active Application Discontinuation
- 2002-05-17 CA CA002443437A patent/CA2443437A1/en not_active Abandoned
- 2002-05-17 MX MXPA03010523A patent/MXPA03010523A/en unknown
- 2002-05-17 AR ARP020101830A patent/AR036154A1/en not_active Suspension/Interruption
- 2002-05-17 YU YU91403A patent/YU91403A/en unknown
- 2002-05-17 PL PL02365735A patent/PL365735A1/en not_active Application Discontinuation
- 2002-05-17 HU HU0400030A patent/HUP0400030A3/en unknown
- 2002-05-17 EP EP02735364A patent/EP1397387A1/en not_active Ceased
- 2002-05-17 EA EA200301169A patent/EA200301169A1/en unknown
- 2002-05-17 CN CNA028101561A patent/CN1541226A/en active Pending
- 2002-05-17 JP JP2002592353A patent/JP2005504517A/en active Pending
- 2002-05-17 CZ CZ20033476A patent/CZ20033476A3/en unknown
- 2002-05-17 SK SK1559-2003A patent/SK15592003A3/en not_active Application Discontinuation
- 2002-05-17 PE PE2002000422A patent/PE20021098A1/en not_active Application Discontinuation
- 2002-05-17 BR BR0210905-0A patent/BR0210905A/en not_active Expired - Fee Related
-
2003
- 2003-09-22 ZA ZA200307365A patent/ZA200307365B/en unknown
- 2003-11-10 EC EC2003004838A patent/ECSP034838A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002094879A1 (en) | 2002-11-28 |
| HUP0400030A3 (en) | 2006-02-28 |
| CA2443437A1 (en) | 2002-11-28 |
| ZA200307365B (en) | 2004-05-10 |
| MXPA03010523A (en) | 2004-07-01 |
| EP1397387A1 (en) | 2004-03-17 |
| YU91403A (en) | 2006-05-25 |
| EA200301169A1 (en) | 2004-06-24 |
| BR0210905A (en) | 2004-06-08 |
| PL365735A1 (en) | 2005-01-10 |
| JP2005504517A (en) | 2005-02-17 |
| SK15592003A3 (en) | 2004-06-08 |
| AR036154A1 (en) | 2004-08-18 |
| CN1541226A (en) | 2004-10-27 |
| ECSP034838A (en) | 2003-12-24 |
| HUP0400030A2 (en) | 2004-04-28 |
| CZ20033476A3 (en) | 2004-05-12 |
| EE200300569A (en) | 2004-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20021098A1 (en) | CD44v6 SPECIFIC ANTIBODIES | |
| CY1118467T1 (en) | HIGH CONCENTRATION OF ANTIBODIES AND PROTEIN PACKAGES | |
| ATE382053T1 (en) | SYSTEM FOR ANTIBODIES EXPRESSION AND SYNTHESIS | |
| CY1114851T1 (en) | IL-1BIT BINDING antibodies and their fragments | |
| PE20070684A1 (en) | RANKL-PTH / PTHrP ANTIBODY CHEMERICAL MOLECULES | |
| EP1067182A3 (en) | Secretory protein or membrane protein | |
| ATE510011T1 (en) | NEW FUNGAL PROTEINS AND THE NUCLEIC ACIDS THAT ENCOD THEM | |
| DK2014678T3 (en) | KDR peptides and vaccines containing them | |
| BRPI0616712B8 (en) | method for amidating polypeptides with basic amino acid c-termini by specific endoproteases | |
| IL172729A0 (en) | Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins | |
| DE69839444D1 (en) | SMAD 6 AND ITS APPLICATIONS | |
| ES2085993T3 (en) | PROTEIN ASSOCIATED WITH ACUTE PANCREATITIS, MEANS FOR THE DIAGNOSIS OF ACUTE PANCREATITIS. | |
| CY1106070T1 (en) | POLYMORPHIMS IN THE HUMAN ORGANIC ANION TRANSPORTER C GENE (OATP-C) - (ORGANIC ANION TRANSPORTER C GENE) | |
| CY1110848T1 (en) | NOGO HUMAN ANTI-ANTIQUE AND THE PHARMACEUTICAL OF THE USE | |
| CY1109207T1 (en) | ECHINOCANDINI PROCEDURE | |
| CY1114526T1 (en) | PROTEASE CONSTRUCTION PROTEINS AND USE OF THESE | |
| DE60335726D1 (en) | CHROMOPROTEIN AND FLUORO PROTEINS | |
| DE60122562D1 (en) | NUCLEIC ACIDS CODED FOR STICHODACTYLIDAE CHROMOPROTEINS | |
| DK1485481T3 (en) | Fluorescent protein from Aequorea Coerulescens and uses thereof | |
| DK1576157T3 (en) | Fluorescent proteins from Copepode species and methods for using the same | |
| BRPI0407031A (en) | Compositions and methods for cancer treatment using igsf9 and liv-1 | |
| CO4520255A1 (en) | TUMOR THERAPY THROUGH LYMPHOCYTES T CYTOTOXIC TRANSFER ADOPTIVES SPECIFIC CD44V | |
| DE60120187D1 (en) | SHORTEN BARD1 PROTEIN AND ITS DIAGNOSTIC AND THERAPEUTIC APPLICATIONS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |